Abstract: Provided herein are pharmaceutically acceptable compositions containing macrolide antibiotics, in particular azithromycin. In particular, compositions containing azithromycin with low toxicity, especially for administration to felines, are provided herein.

Abstract: Products containing a nicotine-polymer complex are provided herein, which can optionally further include one or more, different nicotine components. Certain such products are pouched products including an outer water-permeable pouch defining a cavity containing a composition comprising a water-soluble component capable of being released through the water-permeable pouch. The disclosure further provides methods of preparing such products.

Abstract: Provided herein are pharmaceutically acceptable compositions containing macrolide antibiotics, in particular azithromycin. In particular, compositions containing azithromycin with low toxicity, especially for administration to felines, are provided herein.

Abstract: The disclosure provides a multi-layered tablet configured for oral use, the tablet including a first layer including an effervescent composition and a second layer including a non-effervescent composition. The effervescent composition includes an effervescent material; one or more fillers in a total amount of at least about 30% by weight, the one or more fillers including at least one sugar alcohol; and at least one active ingredient. The non-effervescent composition includes one or more fillers in a total amount of at least about 30% by weight, the one or more fillers including at least one sugar alcohol; a binder; and a second active ingredient.

Abstract: The disclosure provides solid products configured for oral use. The products contain a lipophilic active ingredient, a self-emulsifying delivery system (SEDS), a binder, and at least one sugar, at least one sugar alcohol, or a combination thereof. The SEDS is configured to provide droplets including the lipophilic active ingredient, the droplets have a D90 value in a range from about 10 to about 1000 nm.

Abstract: Provided herein are pharmaceutically acceptable compositions containing macrolide antibiotics, in particular azithromycin. In particular, compositions containing azithromycin with low toxicity, especially for administration to felines, are provided herein.

Abstract: Provided herein are pharmaceutically acceptable compositions containing a selective cyclooxygenase-2 (COX-2) inhibitor (coxib) and optionally buprenorphine. In particular, compositions containing a coxib formulated for oral, topical or subcutaneous administration to treat pain or inflammation are described.

Abstract: Provided herein are chewable oral formulations including pimobendan for use in mammals to treat cardiac disorders.

Abstract: Provided herein are pharmaceutically acceptable compositions containing macrolide antibiotics, in particular azithromycin and tulathromycin. In particular, compositions containing azithromycin or tulathromycin with low toxicity, especially for administration to canines, are provided herein.

Abstract: Provided herein are long-acting, non-aqueous pharmaceutically acceptable compositions of active ingredients for topical administration.

Abstract: Provided herein are long-acting, non-aqueous pharmaceutically acceptable compositions of active ingredients for subcutaneous injection.

Abstract: Provided herein are pharmaceutically acceptable compositions containing macrolide antibiotics, in particular azithromycin. In particular, compositions containing azithromycin with low toxicity, especially for administration to felines, are provided herein.

Abstract: Provided herein are pharmaceutically acceptable compositions containing macrolide antibiotics, in particular azithromycin. In particular, compositions containing azithromycin with low toxicity, especially for administration to felines, are provided herein.

Abstract: Provided herein are pharmaceutically acceptable compositions containing macrolide antibiotics, in particular azithromycin. In particular, compositions containing azithromycin with low toxicity, especially for administration to felines, are provided herein.

Abstract: Provided herein are pharmaceutically acceptable compositions containing macrolide antibiotics, in particular azithromycin. In particular, compositions containing azithromycin with low toxicity, especially for administration to felines, are provided herein.

Abstract: Provided herein are pharmaceutically acceptable compositions containing macrolide antibiotics, in particular azithromycin and tulathromycin. In particular, compositions containing azithromycin or tulathromycin with low toxicity, especially for administration to canines, are provided herein.

Abstract: Provided herein are pharmaceutically acceptable compositions containing macrolide antibiotics, in particular azithromycin. In particular, compositions containing azithromycin with low toxicity, especially for administration to felines, are provided herein.